The effect of oral Kallikrein treatment on sperm motility in asthenozoospermia.
Nineteen men with asthenozoospermia were treated with oral Kallikrein (600 U daily for 12 weeks) and sperm motility evaluated in 16  of these patients.  No quantitative or qualitative improvement motility or the duration of motility was found in semen samples examined 4, 12, and 24 weeks after starting the treatment.  Two pregnancies occurred 11 and 40 weeks after discontinuation of the Kallikrein therapy.
D000328:Adult; D006801:Humans; D007248:Infertility, Male / Q000188:drug therapy*; D007610:Kallikreins / Q000494:pharmacology*; D008297:Male; D013081:Sperm Motility / Q000187:drug effects*; D013997:Time Factors
D007610:Kallikreins